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Abstract
Background Resistance to recombinant human erythropoi-
etin (rhEPO) occurs in some chronic kidney disease (CKD)
patients, which may be due to enhanced systemic inflam-
matory response and to the erythropoiesis-suppressing
effect of pro-inflammatory cytokines, some of which are
produced by T cells.
Aim of study The aim of this study was to investigate the
relationship between resistance to rhEPO therapy in
hemodialysis CKD patients and inflammatory markers [C-
reactive protein (CRP), soluble interleukin (IL)-2 receptor
(sIL2R), and serum albumin levels], blood cell counts, T-
cell phenotype, cytokine production by T cells, and serum
cytokine levels.
Materials and Methods We studied 50 hemodialysis CKD
patients, 25 responders and 25 nonresponders to rhEPO,
and compared them to each other and with 25 healthy
controls. When compared to controls, CKD patients
showed increased serum levels of CRP, IL-6, and sIL2R
and a T-cell lymphopenia, due to decreased numbers of
both CD4+ and CD8+ T cells. T cells from CKD patients
had an immunophenotype compatible with chronic T-cell
stimulation as shown by the increased percentage of
CD28−, CD57+, HLA-DR+, CD28−HLA-DR+, and CD57+
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HLA-DR+ T cells and produce higher levels of IL-2, INF-γ,
and TNF-α after short-term in vitro stimulation, although
Th1 cytokines were not detectable in serum. Statistically
significant differences were found between responders and
nonresponders to rhEPO therapy for total lymphocyte and
CD4+ T-lymphocyte counts, albumin (lower in nonrespond-
ers) and CRP (higher in nonresponders) levels.
Conclusion CKD patients under hemodialysis present with
raised inflammatory markers and decrease of total lympho-
cyte and CD4+ T-lymphocyte counts when compared with
controls. Some of those markers are even further enhanced
in nonresponders to rhEPO therapy patients, but resistance
to this therapy cannot be justified by a Th1 polarized T-cell
response.
Keywords rhEPO . Lymphocytes . Inflammation .
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Introduction
Despite the technological advances in hemodialysis proce-
dures and medical support in the last years, the mortality
and morbidity of patients with chronic kidney disease
(CKD) remain 10 to 20 times higher than that found in
general population, and anemia is still an independent risk
factor [1–6].
In the last two decades, the institution of recombinant
human erythropoietin (rhEPO) therapy allowed the correc-
tion of the anemia in the majority of CKD patients,
consequently reducing its associated complications and
improving significantly the quality of life. However, more
than 25% of these patients require high doses of rhEPO,
and about 5% to 10% of them do not respond to the therapy
[4, 5–8]. Many factors were described to be associated with
rhEPO therapy resistance, namely, iron, vitamin B12, or
folate deficiencies, blood loss, hyperparathyroidism, oxida-
tive stress, aluminum toxicity, infection, and inflammatory
conditions [3, 6–11].
Inflammatory stimuli induce the release of cytokines,
which in turn causes many systemic changes, including
increased synthesis and release of positive acute-phase
proteins, such as C-reactive protein (CRP), as well as
suppression of negative ones, such as albumin and
transferrin [6–11]. The causes for the inflammatory re-
sponse in hemodialysis patients are not obvious. There are
several potential sources, including bacterial contamination
of the dialyser, dialyser membrane incompatibility, and
infections of the vascular access. However, the dialysis
procedure may only be partially responsible because even
patients with renal insufficiency who are not yet on dialysis
have raised inflammatory markers that rise further after
starting regular hemodialysis treatment [3, 12, 13]. This
inflammatory response may mobilize iron from erythropoi-
esis traffic to store sites within the reticuloendothelial
system, inhibit erythroid progenitor proliferation and
differentiation, blunt the response to erythropoietin, and
accelerate removal of erythrocytes coated with immune
complexes or immunoglobulins. The erythropoiesis-sup-
pressing effect of the increased activity of pro-inflammatory
cytokines associated to this inflammatory condition has
been proposed as an important factor associated to rhEPO
therapy resistance [3, 6, 7, 12, 14, 15]. Pro-inflammatory
cytokines such as interleukin (IL)-1, IL-2, IL-4, IL-6, tumor
necrosis factor (TNF)-α, and interferon (INF)-γ diminish
colony formation of burst-forming (BFU-Es) and colony-
forming (CFU-Es) unit-erythroid cells, suggesting that
these cytokines may cause suppression of erythropoiesis
[3, 16, 17].
Besides inflammation, end-renal failure induces a clin-
ical state of immunodeficiency associated with a higher
incidence of infections and a higher mortality due to
infectious complications. This immunodeficiency is char-
acterized by a deficient response to some vaccinations,
namely, hepatitis B virus. The mechanism responsible for
this immune defect is still unknown. However, it is known
that lymphopenia is associated to end-renal failure, occur-
ring in the B- and T-lymphocyte compartment, probably
due to increased apoptosis [18–20].
There are a considerable number of papers regarding the
associations between inflammation and resistance to rhEPO
therapy. However, only a few investigated at the same time
inflammatory markers, T-cell phenotype, T-cell cytokine
production, and cytokine serum levels, and most of these
included a very limited number of patients. Furthermore,
therapeutic and hemodialysis procedure approaches
changed in the last few years, namely, concerning hemo-
dialysis membrane biocompatibility, and these changes
could influence the causes of rhEPO resistance.
The aim of this study was to investigate the relationship
between resistance to rhEPO therapy and inflammatory
markers, T-cell activation-related phenotype, cytokine pro-
duction by T cells, and serum cytokine levels in hemodi-
alysis CKD patients.
Materials and Methods
Subjects and Samples
Seventy-five individuals were included in this study: 50
hemodialysis CKD patients (25 responders and 25 non-
responders to rhEPO therapy) and 25 healthy controls. The
rhEPO maintenance dose for responder patients was 7.51±
6.52 U kg−1 week−1 Hb−1 and for nonresponders was 59.40±
23.31 U kg−1 week−1 Hb−1.
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Blood samples were collected before hemodialysis, with
and without anticoagulant [ethylenediamine tetraacetic acid
(EDTA) and sodium/lithium heparine] to obtain whole
blood, plasma, and serum.
Classification of CKD patients as responders or non-
responders was performed in accordance with the European
Best Practice Guidelines [21], which defines resistance to
rhEPO as a failure to achieve target hemoglobin levels (11–
12 g/dl) with doses of rhEPO higher than 300 IU kg−1
week−1 of epoetin or 1.5 μg kg−1 week−1 of darbopoietin-α.
Besides rhEPO therapy, all patients were under iron and
folate prophylactic therapies, in accordance to the recom-
mendations of European Best Practice Guidelines [21] to
avoid nutrient erythropoietic deficiencies.
The causes of renal failure in patient population were as
follows: diabetic nephropathy (n=16), chronic glomerulone-
phritis (n=6), polycystic kidney disease (n=5), hypertensive
nephrosclerosis (n=3), obstructive nephropathy (n=3), py-
elonephritis associated with neurogenic bladder (n=1),
nephrolithiasis (n=1), chronic interstitial nephritis (n=1),
Alport syndrome (n=1), renal vascular disease due to
polyarteritis (n=1), and uncertain etiology (n=12). All
patients used high-flux polysulfone FX-class dialysers
(Fresenius Medical Care, Bad Homburg, Germany). No
statistically significant differences where found between
responders and nonresponders among CKD patients
concerning to age, gender, body weight, body mass index,
time on dialysis, urea reduction ratio, Kt/V and parathyroid
hormone serum levels.
Patients with malignancy, hematological disorders, sys-
temic autoimmune diseases, and acute infections were
excluded. None of the patients were under vitamin-D
therapy. All patients gave their informed consent to
participate in this study.
Healthy volunteers, with normal hematological and
biochemical values, without any history of renal or
inflammatory disease, were used as normal controls and,
as far as possible, were age- and gender-matched with CKD
patients.
Assays
Hemoglobin (Hb) and white blood cell (WBC) count was
measured using an automatic counter (Sysmex K1000,
Hamburg, Germany), and leukocyte differential counts
were evaluated in Wright-stained blood films. Serum CRP
was measured by immunoturbidimetry (CRP latex HS
Roche kit, Roche Diagnostics). Enzyme-linked immuno-
sorbent assay was used for measurement of serum soluble
interleukin 2 receptor (sIL2R; Human IL-2 SRα, R&D
systems, Minnesota, USA). Serum albumin levels were
measured using a colorimetric assay end-point method
(Albumin Plus; Roche GmbH, Mannheim, Germany), and
the immunoglobulins were quantified by immunoturbidim-
etry (Tina-quant IgA, Tina-quant IgG, and Tina-quant IgM,
Roche GmbH, Mannheim, Germany).
Flow Cytometry
T-cell cytokine production Heparinised blood cells were
cultured for 4 h in Roswell Park Memorial Institute (RPMI)
1640 medium at 37°C in a 5%CO2 and 95% humidity sterile
environment in the presence of 25 ng/ml of phorbol-12
myristate 13-acetate, 1 μg/ml of ionomycin, and 10 μg/ml
of brefeldin A (stimulated samples) or only with brefeldin
A (unstimulated samples). Immediately after the incubation
period, cells were stained with allophycocyanin (APC)
conjugated anti-CD3 and fluorescein isothiocyanate (FITC)
conjugated anti-CD8 mouse anti-human monoclonal anti-
bodies [MAbs; Becton Dickinson, Biosciences (BDB), San
Jose, CA, USA] for 15 min in the dark at room temperature.
After incubation, cells were washed once in 2 ml of
phosphate-buffered saline (PBS). After discarding the
supernatant, cells were fixed, permeabilized, and stained
with phycoerythrin (PE) conjugated MAbs directed against
human cytokines (IL-2, TNF-α, and INF-γ) or PE-
conjugated isotype-matched MAbs reagents (negative con-
trols; Pharmingen, San Diego, CA, USA). For this purpose,
the Fix & Perm reagent (Caltag, San Francisco, CA, USA)
was used, strictly following the recommendations of the
manufacturer. Once stained, cells were washed once in 2 ml
of PBS, suspended in 0.5 ml of PBS, and analyzed in the
flow cytometer.
T-cell phenotype Cell surface markers were evaluated by
flow cytometry with a whole-blood stain-lyse-and-then-
wash method, using the florescence-activated cell sorting
(FACS) lysing solution (BDB). Cells were stained with
anti-CD8 APC or anti-CD4 APC, anti-CD28 PE-cyanin 5
(PC5), anti-HLA-DR PE, and anti-CD57 FITC MAbs
(BDB). HLA-DR and CD57 expression were used to
evaluate early and late T-cell activation, and absence of
CD28 expression on T lymphocytes was used to quantify
the fraction of memory effector T cells/large granular
lymphocytes [22–25].
Serum cytokine levels IL-2, IL-4, IL-6, IL-10, TNF-α, and
INF-γ serum levels were quantified using the BD™
Cytometric Bead Array Human Th1/Th2 Cytokine Kit II
(BDB).
Data acquisition and analysis Data acquisition was
performed in a FACSCalibur flow cytometer, equipped
with a 488-nm argon ion and a 635-nm red diode laser,
using the CellQUEST™ software program (BDB). For T-
cell phenotype and T-cell cytokine production analysis,
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the Paint-A-Gate PRO software program (BDB) was
used. To quantify the expression of costimulatory
molecules and activation-related markers on T cells, the
percentage of HLA-DR+, CD28+, and CD57+ cells were
recorded after gating for CD8+ and CD4+ T lymphocytes.
Evaluation of cytokine production by CD8+ and CD4+ T
cells was based on the percentage of cytokine+ cells within
CD3+ CD8+ and CD3+ CD8− lymphocytes, respectively.
Serum cytokine levels analysis was performed using the
BDTM CBA Software.
Statistical Analysis
For statistical analysis, we used the Statistical Package for
Social Sciences, version 14.0. Kolmogorov–Smirnov sta-
tistics was used to evaluate sample normality distribution.
Multiple comparisons between groups were performed by
one-way analysis of variance supplemented with Tukey’s
honestly significant difference (HSD) post-hoc test. For
single comparisons, we used the Student’s t test whenever
the parameters presented a Gaussian distribution and the
Table I Blood Cell Count and Immunoglobulin Serum Levels
Healthy Controls
(n=25)
CKD Patients
Total (n=50) rhEPO Responders (n=25) rhEPO Nonresponders (n=25)
Hb (g/dl) 14.1±1.3 (12.0–17.0) 11.1±1.8 (7.1–15.5)* 11.9±1.5 (9.5–15.5)* 10.3±1.7 (7.1–11.9)*,***
White blood cells (109/l) 5.8±1.6 (3.5–9.6) 6.2±2.2 (3.0–12.3) 6.4±1.9 (4.2–11.5) 6.0±2.4 (3.0–12.3)
Lymphocytes (109/l) 2.2±0.7 (1.1–3.5) 1.4±0.6 (0.4–3.1)* 1.6±0.5 (0.5–3.0)** 1.2±0.6 (0.4–3.1)*,***
CD3+ T cells (109/l) 1.6±0.7 (0.5–3.0) 1.0±0.5 (0.2–2.4)** 1.2±0.6 (0.2–2.4) 0.9±0.5 (0.2–2.2)**,***
CD4+ T cells (109/l) 1.1±0.5 (0.3–2.2) 0.7±0.3 (0.1–1.16)** 0.8±0.4 (0.1–1.6)** 0.6±0.3 (0.1–1.13)**,***
CD8+ T cells (109/l) 0.5±0.2 (0.2–0.8) 0.3±0.2 (0.1–0.9)** 0.3±0.2 (0.1–0.7) 0.3±0.2 (0.1–0.9)**
CD4 /CD8 ratio 2.7±1.0 (1.3–4.2) 3.0±1.4 (0.8–7.9) 2.9±1.7 (1.2–7.9) 2.6±1.3 (0.8–6.0)
Monocytes (109/l) 0.2±0.1 (0.1–0.4) 0.4±0.2 (0.2–0.9)** 0.4±0.1 (0.2–0.7)* 0.3±0.2 (0.2–0.9)
Neutrophils (109/l) 3.0±1.0 (1.5–5.2) 4.1±1.7 (1.8–8.9)** 4.1±1.7 (2.0–8.9)** 4.1±1.8 (1.8–8.3)**
Eosinophils (109/l) 0.2±0.3 (0.0–1.6) 0.2±0.2 (0.0–1.1) 0.2±0.2 (0.0–1.1) 0.2±0.1 (0.0–0.5)
Neutrophil/Lymphocyte ratio 1.37±0.51 (0.56–2.66) 3.34±1.92 (0.96–8.25)* 2.80±1.14 (1.28–8.19)* 3.88±2.05 (0.96–8.25)*,***
IgG (mg/dl) 977±161 (688–1279) 1078±353 (509–2163) 1043±315 (633–2163) 1112±392 (509–1986)
IgA (mg/dl) 215±86 (77–387) 275±126 (91–653) 275±119 (91–542) 275±136 (104–653)
IgM (mg/dl) 122±65 (33–277) 106±78 (29–518) 100±57 (29–276) 113±95 (30–518)
Results are presented as mean±one standard deviation (minimum–maximum)
*p<0.0001 vs controls
**p<0.05 vs controls
***p<0.05 vs responders
Table II Expression of HLA-DR, CD57 and CD28 Molecules on Blood CD4+ and CD8+ T Cells
Healthy Controls (n=12) CKD Patients
Total (n=24) rhEPO Responders (n=12) rhEPO Nonresponders (n=12)
% CD4+ T cells
HLA-DR+ 8.7±4.2 (4.7–18.6) 17.4±7.4 (6.8–41.3)* 16.4±9.1 (6.8- 41.3)* 18.8±4.2 (12.8–25.8)*
CD57+ 2.4±3.4 (0.4–12.6) 9.0±7.7 (0.6–32.0)* 8.2±8.9 (0.7–32.0)* 10.8±6.7 (0.6–22.1)*
CD28− 0.9±0.9 (0.3–3.1) 7.0±7.0 (0.1–23.5)* 6.6±5.5 (0.1–17.0)* 8.6±8.5 (0.1–23.5)*
CD57+ HLA-DR+ 23.7±13.6 (0.3–44.2) 44.9±19.8 (13.9–8.3)* 43.3±17.8 (19.7–68.3)* 47.2±23.7 (13.9–67.4)*
CD28− HLA-DR+ 25.3±23.2 (9.7–72.2) 43.6±19.5 (16.7–77.0)* 42.8±20.4 (19.9–69.1)* 44.7±19.8 (16.7–77.0)*
% CD8+ T cells
HLA-DR+ 25.1±12.8 (10.4–44.4) 45.7±16.5 (17.3–73.5)* 41.4±17.4 (17.3–65.2)* 51.5±14.1 (32.1–73.5)*
CD57+ 21.1±13.5 (4.9–43.4) 38.3±15.9 (14.2–60.0)* 34.8±11.2 (16.4–52.9)* 44.7±19.4 (14.2–60.0)*
CD28− 28.4±13.7 (11.8–57.2) 44.0±22.9 (7.5–85.7)* 41.3±19.0 (15.0–64.2)* 49.5±26.9 (7.5–85.7)*
CD28− HLA-DR+ 33.7±18.7 (0.1–61.3) 54.8±19.3 (22.6–86.0)* 50.4±18.0 (22.6–73.4)* 58.9±20.7 (31.4–86.0)*
CD57+ HLA-DR+ 35.1±21.2 (0.1–66.2) 54.9±18.2 (18.0–81.7)* 50.2±16.2 (18.0–72.1) 58.5±19.8 (27.2–81.7)*
Results are presented as mean±one standard deviation (minimum–maximum)
*p<0.05 vs controls
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Mann–Whitney U test in the case of a non-Gaussian
distribution. Significance was accepted at p less than 0.05.
Results
The hematological characteristics of the three groups studied
are summarized in Table I. Hemodialysis CKD patients were
more anemic than controls, and nonresponder patients were
even more anemic than responder patients. No difference
was found between the three groups of patients concerning
the WBC count. However, CKD patients showed lympho-
penia as well as increased monocyte and neutrophil counts
and increased neutrophil/lymphocyte ratio, as compared to
controls. Lymphopenia observed in CKD patients results at
least in part from a decrease in total circulating CD3+ T
lymphocytes and affects both the CD4+ and the CD8+ T-cell
subsets (p<0.05). Statistically significant differences were
found between responders and nonresponders to rhEPO
therapy, concerning total lymphocyte and CD4+ T-cell counts
(lower for nonresponders; p<0.05), and to neutrophil/
lymphocyte ratio (higher for nonresponders; p<0.05). No
statistically significant differences were found between the
three groups of individuals concerning immunoglobulin
serum levels (Table I).
CKD patients showed a statistically significant increase
(p<0.05) in the proportion of CD28−, CD57+, HLA-DR+,
CD28−HLA-DR+ and CD57+ HLA-DR+ T cells when
compared to controls, both in the CD4+ and in the CD8+
T-cell compartments (Table II). No statistically significant
differences were found between responders and nonrespond-
ers to rhEPO concerning expression of CD28 co-stimulatory,
and CD57 and HLA-DR cell-surface activation-related
molecules.
CKD patients showed a statistically significant increase
in serum levels of CRP, sIL2R, and IL-6 as compared to
Table III Inflammatory Markers and Serum Cytokine Levels of Studied Subjects
Healthy Controls (n=25) CKD patients
Total (n=50) rhEPO Responders (n=25) rhEPO Nonresponders (n=25)
Albumin (g/dl) NM 3.8±0.4 (2.7–4.5) 4.0±0.4 (2.9–4.5) 3.7±0.4 (2.7–4.2)***
CPR (mg/dl) 1.75 (0.76–4.47) 5.75 (1.90–14.01)* 3.20 (1.73–7.23)** 10.14 (3.82–38.99)*,***
sIL2R (nmol/l) 758±235 (324–1290) 4199±1762 (1795–8377)* 4005±1835 (1795–8377)* 4394±1701 (2232–8265)*
IL-2 (pg/ml) 2.5±3.0 (0.0–9.3) ND ND ND
IL-4 (pg/ml) ND ND ND ND
IL-6 (pg/ml) 1.90 (0–3.75) 7.80 (3.85–15.05)* 5.75 (3.83–13.95)* 8.80 (4.55 – 21.30)*
IL-10 (pg/ml) 1.20 (0–2.80) 1.10 (0–2.15) 0.0 (0–1.6) 1.40 (0–2.25)***
TNF-α (pg/ml) 1.40 (0–3.55) ND ND ND
INF-γ (pg/ml) ND ND ND ND
Results are presented as mean±one standard deviation (minimum–maximum) or as median values (inter-quartile range). Zero values represent
samples in which serum levels of the mentioned cytokine were undetectable: IL-2 (7 out of 18 controls’ and all patients’ samples); IL-6 (7 out of
18 controls’ samples); TNF-α (8 out of 18 controls’ and all patients’ samples); IL-10 (8 out of 18 controls’ and 25 out of 50 patients’ samples; 17
out of 25 responders and 8 out of 25 nonresponders)
NM Not made; ND not detected (limit of detection <1 pg/ml)
*p<0.0001, vs controls
**p<0.05, vs controls
***p<0.05 vs responders
Fig. 1 Illustrative dot plots showing the IL-2, INF-γ, and TNF-α expression on CD8+ and CD8− cells, after gating on CD3+ T lymphocytes. Red
dots CD3+ CD8− Cytokine−; yellow dots CD3+ CD8+ Cytokine−; violet dots CD3+ CD8− Cytokine+; black dots CD3+ CD8+ Cytokine+ T cells
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controls (p<0.0001; Table III). In contrast, serum levels of
IL-2 and TNF-α were lower in CKD patients, these Th1
cytokines being detected in 11 and 10 out of 18 control
samples, respectively, whereas in none of the CKD
patients’ samples. Concerning IL-10, no differences were
found between CKD patients and controls, this cytokine
being detected in 10 out of 18 controls’ and in 25 out of 50
CKD patients’ samples. Serum levels of IL-4 and INF-γ
were undetectable in both control’s and patient’s samples.
T cells from CKD patients produced higher amounts of
IL-2, TNF-α, and IFN-γ after short-term in vitro stimula-
tion as compared to controls (Figs. 1 and 2). Statistically
significant differences (p<0.05) were observed for IL-2,
INF-γ, and TNF-α in the case of CD8+ T cells but only for
IL-2 and TNF-α in the case of CD4+ T cells.
When comparing responders and nonresponders CKD
patients, we found that nonresponders showed decreased
serum levels of albumin (p<0.01) and increased CRP (p<
0.05) and IL-10 (p<0.05) serum levels, this cytokine being
detected in 17 of the 25 analyzed samples, as compared to
8 out of the 25 responder’s samples (Table III). No
differences were observed between responders and non-
responders in the levels of the other soluble mediators,
neither on the ability to produce Th1 cytokines after short-
term in vitro stimulation.
Discussion
In this study, we demonstrated that CKD patients under
hemodialysis treatment show neutrophilia, increased neu-
trophil/lymphocyte ratio, and higher levels of IL-6, sIL2R,
and CRP pro-inflammatory molecules in the serum, and
decreased albumin serum levels, confirming the presence of
an inflammatory process. The fact that nonresponders had
higher CRP and lower albumin serum levels as compared to
responders would suggest a relationship between resistance
to rhEPO therapy and the magnitude of the inflammatory
response, already described in literature [13, 14, 26–28].
In addition, this study demonstrated that CKD patients
have lower number of total lymphocytes, CD4+ and CD8+
T lymphocytes, when compared to controls, although
statistically significant differences between responders and
nonresponders to rhEPO therapy were found only for total
lymphocytes and CD4+ T cells, which were lower in
nonresponders. T and B lymphopenia have been previously
described in literature in CKD patients, associated with
renal-replacement therapy [29, 30]. B lymphopenia has
been associated with stage 5 of CKD and T lymphopenia to
a selective depletion of naïve CD4+ and CD8+ T lympho-
cytes and CD4+ central memory population [31]. There are
some possible explanations for lymphocyte depletion in
CKD patients, namely, increased turnover, disturbance of
lymphocyte homeostasis due to uremia and increased
peripheral lymphocyte apoptosis associated with activation
stimulus [14, 31–35]. This lymphocyte depletion could be
Fig. 2 Percentage of Cytokine+ cells among CD4+ (CD3+ CD8−; white
bars) and CD8+ (CD3+ CD8+; grey bars) T cells after short-term in
vitro stimulation with phorbol-12 myristate 13-acetate plus Ionomycin
in controls, as well as in responder and nonresponder CKD patients.
Boxplot shows median value (horizontal line in box) and first and third
quartiles (inferior and superior lines of the box, respectively)
J Clin Immunol
exacerbated in nonresponders, justifying the difference
found between the two groups of patients concerning total
lymphocytes and CD4+ T lymphocytes.
Increased proportions of both early (HLA-DR) and late-
activation (CD57) markers on both CD4+ and CD8+ T-cell
subsets are compatible with an enhanced continuous
activation state in CKD patients [22]. This probably results
from persistent antigen stimulation/chronic inflammation
associated with hemodialysis and/or chronic renal failure,
which probably also justifies the increase in the fraction of
memory effector T cells/large granular lymphocytes, as
shown by the higher percentage of CD4+/CD28− and CD8+/
CD28− T cells observed in hemodialysis CKD patients
when compared to controls [25]. Curiously, higher levels of
expression of HLA-DR and CD57 were observed not only
on total CD4+ and CD8+ T cells, but also on CD4+/CD28−
and CD8+/CD28− T-cell subsets. On literature, we found
only one paper [14] describing cytokine and CD28 T-cell
expression in CKD patients, and the authors showed
statistically significant differences between responders and
nonresponders to rhEPO therapy. However, in our study, no
differences were found between the two groups of patients.
These differences could be due to the difference between
studied CKD patient population, namely, concerning the
existence of other rhEPO resistance-related factors.
In accordance to their enhanced activation state, T cells
from CKD patients under hemodialysis treatment show an
enhanced ability to produce Th1-related cytokines (IL-2,
INF-γ, and TNF-α) after short-term in vitro stimulation,
although these cytokines were undetectable in serum. This
increased capacity to produce Th1 cytokines could justify, at
least in part, the anemia found in CKD patients. In fact, these
cytokines are described to be associated to an inhibitory
effect to the formation of CFU-Es and BFU-Es [12–14, 16].
However, this enhanced capacity to produce cytokines is not
associated to the refractoriness to rhEPO therapy, as
previously described in nonresponder CKD patients [7].
In conclusion, our results show that CKD patients have
an enhanced inflammatory response as well as evidence of
Th1 polarized T-cell activation process and suggest that
resistance to rhEPO therapy is associated to inflammation
markers and CD4+ lymphopenia but cannot be ascribed to
an enhanced T-cell activation state neither to a mediated
Th1 response. Further studies are required to understand the
mechanism of lymphocyte loss and its consequences in the
response to rhEPO therapy.
Acknowledgments The authors are grateful to Amgen for financial
support and to the nurses of Fresenius Medical Center, Dinefro-
Diálises e Nefrologia, SA and Uninefro-Sociedade Prestadora de
Cuidados Médicos e de Diálise, SA, for technical support. This study
was supported by a PhD grant (SFRH/BD/27688/2006) attributed to
E. Costa by Fundação para a Ciencia e Tecnologia (FCT) and Fundo
Social Europeu.
References
1. Kerr PG. Renal anaemia: recent developments, innovative
approaches and future directions for improved management.
Nephrology. 2006;11:542–8.
2. Macdougall IC. Present and future strategies in the treatment of
renal anaemia. Nephrol Dial Transpl. 2001;16(suppl 5):50–5.
3. Macdougall IC, Cooper AC. Erythropoietin resistance: the role of
inflammation and pro-inflammatory cytokines. Nephrol Dial
Transplant. 2002;17(Suppl 11):39–43.
4. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of
cardiovascular disease in chronic renal failure. Am J Kidney Dis.
1998;32(suppl 3):S112–9.
5. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre
PE. The impact of anemia on cardiomyopathy morbidity and
mortality in end-stage renal disease. Am J Kidney Dis. 1996;
28:53–61.
6. Smrzova J, Balla J, Bárány P. Inflammation and resistance to
erythropoiesis-stimulting agents—what do we know and what needs
to be clarified. Nephrol Dial Transpant. 2005;20(Suppl 8):viii2–7.
7. Cooper AC, Mikhail A, Lethbridge MW, Kemeny DM, Macdougall
IC. Increased expression of erythropoiesis inhibiting cytokines
(IFN-γ, TNF-α, IL-10, and IL-13) by T cells in patients exhibiting
a poor response to erythropoietin therapy. J Am Soc Nephrol.
2003;14:1776–84.
8. Macdougal IC. Poor response to erythropoietin: practical guide-
lines on investigation and management. Nephrol Dial Transplant.
1995;10:607–14.
9. Drueke TB. R-HuEPO hyporesponsiveness: who and why.
Nephrol Dial Transplant. 1995;10(suppl 2):S62–8.
10. Danielson B. R-HuEPO hyporesponsiveness: who and why.
Nephol Dial Transplant. 1995;10(suppl 2):S69–73.
11. Fishbane S. Hyporesponsiveness to recombinant human erythro-
poietin in dialysis patients. Dial Transplant. 2000;29:545–8.
12. Schindler R, Senf R, Frei U. Influencing the inflammatory
response of haemodialysis patients by cytokine elimination using
large-pore membranes. Nephrol Dial Transplant. 2002;17:17–9.
13. Gunnell J, Yeun JY, Depner TA, Kaysen GA. Acute-phase
response predicts erythropoietin resistance in hemodialysis and
peritoneal dialysis patients. Am J Kidney Dis. 1999;33:63–72.
14. Cooper AC, Breen CP, Vyas B, Ochola J, Kemeny DM,
Macdougall IC. Poor response to recombinant erythropoitin is
associated with loss of T-lymphocyte CD28 expression and
altered interleukin-10 production. Nephrol Dial Transplant.
2003;18:133–40.
15. Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P,
Zingraff J, Moynot A, Verger C, Dahmane D, Groote D, Jungers
P, Dayer JM. Balance between IL-1β, TNF-α, and their specific
inhibitors in chronic renal failure and maintenance dialysis. J
Immunology. 1995;154:882–92.
16. Means RT Jr, Krantz SB. Inhibition of human erythroid colony
forming units by interferons α and β: differing mechanisms
despite shared receptor. Exp Haematol. 1996;24:204–8.
17. Allen DA, Breen C, Yaqoob MM, Macdougall IC. Inhibition of
CFU-E colony formation in uremic patients with inflammatory
disease: role of INF-γ and TNF-α. J Invest Med. 1999;47:204–11.
18. Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation
correlates with expression of apoptosis markers in patients with
end-stage renal disease. J Am Soc Nephol. 2002;13:204–12.
19. Waltzer WC, Bachvaroff RJ, Raisbeck AP, Egelandsdal B, Pullis
C, Shen L, Rapaport FT. Immunological monitoring in patients
with end-stage renal disease. J Clin Immunol. 1984;4:364–8.
20. Litjens NHR, van Druninger CJ, Betjes MGH. Progressive loss of
renal function is associated with activation and depletion of naïve
T lymphocytes. Clinical Immunology. 2006;118:83–91.
J Clin Immunol
21. Locatelli F, Aljama P, Barany P, European Best Practice Guide-
lines Working Group, et al. Revised European best practice
guidelines for the management of anaemia in patients with chronic
renal failure. Nephrol Dial Transplant. 2004;19(Suppl 2):ii1–47.
22. d’Angeac AD, Monier S, Pilling D, Travaglio-Encinoza A, Reme
T, Salmon M. CD57+ T lymphocytes are derived from CD57-
precursors by differentiation occurring in late immune responses.
Eur J Immunol. 1997;24:1503–11.
23. Lima M, Teixeira Mdos A, Queiros ML, Santos AH, Goncalves
C, Correia J, Farinha F, Mendonca F, Soares JM, Almeida J, Orfao
A, Justica B. Immunophenotype and TCR-Vbeta repertoire of
peripheral blood T-cells in acute infectious mononucleosis. Blood
Cells Mol Dis. 2003;30:1–12.
24. Lima M, Almeida J, Teixeira MA, Santos AH, Queiros ML,
Fonseca S, Moura J, Goncalves M, Orfao A, Pinto Ribeiro AC.
Reactive phenotypes after acute and chronic NK-cell activation. J
Biol Regul Homeost Agents. 2004;18:331–4.
25. Romero P, Zippelius A, Kurth I, Pittet MJ, Touvrey C, Iancu EM,
Corthesy P, Devevre E, Speiser DE, Rufer N. Four functionally
distinct populations of human effector-memory CD8+ T lympho-
cytes. J Immunol. 2007;178:4112–9.
26. Bárány P. Inflammation, serum C-reactive protein, and erythro-
poietin resistance. Nephrol Dial Transplant. 2001;16:224–7.
27. Spittle MA, Hoenich NA, Handelman GJ, Adhikarla R, Homel P,
Levin NW. Oxidative stress and inflammation in hemodialysis
patients. Am J Kidney Dis. 2001;38:1408–13.
28. Reddan DN, Klassen PS, Szczech LA, Coladonato JA, O’Shea S,
Owen WF Jr, Lowrie EG. White blood cells as a novel mortality
predictor in haemodialysis patients. Nephrol Dial Transplant.
2003;18:1167–73.
29. Fernandez-Fresnedo G, Ramos MA, Gonzalez-Pardo MC, de
Francisco AL, Lopez-Hoyos M, Aris M. B lymphopenia in uremia
is related to an accelerated in vitro apoptosis and dysregulation of
Bcl-2. Nephrol Dial Transplant. 2000;15:502–10.
30. Kurz P, Kohler H, Meuer S, Hutteroth T, Meyer zum
Buschenfelde KH. Impaired cellular immune response in
chronic renal failure: evidence for a T cell defect. Kidney Int.
1986;29:1209–14.
31. Litjens NHR, van Druningen CJ, Betjes MGH. Progressive
loss of renal function is associated with activation and
depletion of naïve T lymphocytes. Clinical Immunology.
2006;118:83–91.
32. Kang I, Hong MS, Nolasco H, Park SH, Dan JM, Choi JY, Craft J.
Age-associated change in the frequency of memory CD4+ T cells
impairs long term CD4+ T cell responses to influenza vaccine. J
Immunol. 2004;173:673–81.
33. Napolitano LA, Grant RM, Dreeks SG, Schmidt D, De Rosa SC,
Herzenberg LA, Herndier BG, Andersson J, McCune JM.
Increased production of IL-7 accompanies HIV-1-mediated T-cell
depletion: implications for T-cell homeostasis. Nat Med.
2001;7:73–9.
34. Moser B, Roth G, Brunner M, Lilaj T, Deicher R, Wolner E,
Kovarik J, Boltz-Nitulescu G, Vychytil A, Ankersmit HJ.
Aberrant T cell activation and heightened apoptotic turnover in
end-stage renal failure patients: a comparative evaluation between
non-dialysis, haemodialysis, and peritoneal dialysis. Biochem
Biophys Res Commun. 2003;308:581–5.
35. Jiang Q, Li WQ, Aiello FB, Mazzucchelli B, Asefa B, Khaled
AR, Durum SK. Cell biology of IL-7, a key lymphotrophim.
Cytokine Growth Factor Rev. 2005;16:513–33.
J Clin Immunol
